Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
Clinical trial NCT00093210 · COMPLETED
Trial details
- NCT number
- NCT00093210
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.